Skip to main content
Premium Trial:

Request an Annual Quote

Eurogentec Hooks Scorpions Tech from DxS

NEW YORK, Jan. 21 - UK-based pharmacogenomics firm DxS has granted non-exclusive rights to its Scorpions genotyping technology to Eurogentec, according to Eurogentec.

Terms of the agreement call for Eurogentec, of Liège, Belgium, to acquire non-exclusive rights to manufacture and supply the technology to the life-science community, excluding agrochemical firms, the company said in a statement.

DxS receives an undisclosed royalty in exchange. Further financial details of the deal remained undisclosed.

The Scorpions technology "involves a single, instant reaction and avoids competing and/or side reactions" and can process up to 100,000 assays per day, according to DxS.

"We are delighted to have concluded this, our first licensing agreement, with a strong, international provider of genomic research solutions," Steve Little, CEO of DxS, said in a statement in released in early January.

Eurogentec, which markets a range of genomic- and proteomic-based tools and technologies, was founded in 1985 as a spin-off of the University of Liège. It has subsidiaries in France, Germany, the UK, the Netherlands, and a branch office in Switzerland.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.